5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow ENMD 2076: new trials by email Literature Review of ENMD 2076 trials Research Report on ENMD 2076
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma ENMD-2076 - Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 35 | 2015-10-01 | 2025-04-18 |
| A Study of ENMD-2076 in Ovarian Clear Cell Cancers ENMD-2076 - Ovarian Clear Cell Carcinoma | Phase 2 | Completed | University Health Network, Toronto | 40 | 2013-09-01 | 2019-12-13 |
| Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma ENMD-2076 - Advanced, Metastatic | Phase 2 | Completed | University Health Network, Toronto | 25 | 2013-01-01 | 2023-08-01 |
| Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC ENMD-2076 - Triple Negative Breast Cancer | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 41 | 2012-07-01 | 2017-06-26 |
| Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer ENMD-2076 - Ovarian Cancer, Fallopian Cancer | Phase 2 | Completed | CASI pharmaceuticals, Inc. | 64 | 2010-04-01 | 2014-08-06 |
Breast Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Sarcoma (1) · Triple Negative Breast Neoplasms (1)
CASI pharmaceuticals, Inc. (3) · University Health Network, Toronto (2)
Canada (3) · United States (3) · China (1)
Albiruni Razak, MBBS (1) · Amit Oza, M.D. (1) · Ghassan Abou-Alfa, MD (1) · Ken Ren, PhD (1) · Rong Chen, MD (1) · William Gannon, MD, MBA (1)